Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
Twice-yearly azithromycin distribution to children aged 1-59 months reduced all-cause mortality by 14% compared to placebo, even in communities with lower baseline mortality rates and ongoing malaria prevention efforts.
Allergy & Immunology August 29th 2024
In a controlled trial conducted over a six-month period in Mali, subcutaneous administration of the monoclonal antibody L9LS to children aged 6 to 10 achieved an efficacy rate of up to 77% in preventing clinical malaria.
Allergy & Immunology May 6th 2024
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH